A multicentre analysis of efficacy, safety and molecular response correlates of fostamatinib in warm autoimmune haemolytic anaemia and Evans syndrome

J. López; Lipei Shao; Debbie Jiang; Lawrence S. Bailey; Thejaswi Bikkani; Aaron Boothby; Donald C. Moore; I Murakhovskaya; Caroline Piatek; Mauricio Pineda‐Roman; P. Jin; Jacqueline N. Poston; Moritz Stolla; David F. Stroncek; Krystalyn E. Hudson; JB Bussel; Sandhya R. Panch

doi:10.1111/bjh.70434

March 17, 2026British Journal of HaematologyOpen Access

A multicentre analysis of efficacy, safety and molecular response correlates of fostamatinib in warm autoimmune haemolytic anaemia and Evans syndrome

View Full Paper

Ask AI

Bookmark

Share

Key Points

This research aims to evaluate the efficacy and safety of fostamatinib in patients with warm autoimmune hemolytic anemia and Evans syndrome.
Conducted a multicentre retrospective analysis
Evaluated treatment responses and side effects
Assessed molecular response correlates in a patient subset
Achieved a 46% durable response rate
Observed a 73% reduction in steroid use
Reported side effects in 23% of patients, including hypertension and neutropenia
Identified correlations between migration inhibitory factor, naïve T-cells, and treatment response in a subset of eight patients.

Ask about this paper

Answers are grounded in this paper and cite their sources.

Implication

Multicentre analysis reveals fostamatinib efficacy in autoimmune hemolytic anemia, indicating potential treatment benefits.

Abstract

Fostamatinib had 46% durable response, with 73% steroid reduction, in this multicentre retrospective study of refractory wAIHA/ES. Hypertension, gastrointestinal (GI) distress and neutropenia occurred in 23%. Only one patient required drug discontinuation and one patient dose reduction. In an eight-patient subset, migration inhibitory factor (MIF) levels, naïve (CD62Lhi) T-cell and HLA-DRhi monocyte subsets each correlated with treatment response.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

López et al. (2026) studied this question.

synapsesocial.com/papers/69be35386e48c4981c6735dd https://doi.org/10.1111/bjh.70434

View Full Paper

Ask AI

Bookmark

Share

A multicentre analysis of efficacy, safety and molecular response correlates of fostamatinib in warm autoimmune haemolytic anaemia and Evans syndrome

Key Points

Ask about this paper

Implication

Abstract

Discussion

Cite This Study

A multicentre analysis of efficacy, safety and molecular response correlates of fostamatinib in warm autoimmune haemolytic anaemia and Evans syndrome

Key Points

Ask about this paper

Implication

Abstract

Discussion

Cite This Study

Keep reading

Keep reading